Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV16-E7-T512
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
HPV16-E7-T512 is a transcription activator-like effector nucleases (TALEN)-edited plasmid designed to target the E7 epitope of human papillomavirus type 16 (HPV16). This gene-editing approach aims to disrupt or modify the viral E7 oncogene, which plays a critical role in the development and maintenance of HPV-associated malignancies. By targeting and editing this specific viral sequence, T512 may inhibit tumor growth or promote immune-mediated clearance of infected cells. The therapy represents an investigational gene-editing strategy for treating cancers associated with high-risk HPV infection[1].
02
Targets
pMHC-I (Peptide–MHC class I complex)HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on HPV16-E7-T512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV16-E7-T512.